Becton Dickinson & Co. and BioMedomics said Tuesday they will
launch a new test that can detect current or past exposure to Covid-19,
the illness caused by the new coronavirus, in nearly 15 minutes, part of
a new wave of companies seeking to scale up testing and cut down wait
times for results.
Clinical-diagnostics company BioMedomics has developed and
manufactured the new test, which will be available through Becton
Dickinson. The test will be exclusively distributed by Henry Schein Inc.
Healthcare providers around the U.S. will be able to receive the tests.
The four-stage test won’t require special equipment, the companies
said. It can be used in a laboratory or at a point-of-care facility.
The test will be able to detect antibodies in the blood that are
produced in response to the coronavirus infection. The test can detect
past exposure as well, which could help researchers pinpoint more
precisely the occurrence of the infection in the population.
Though the test has been clinically validated at some hospitals and
labs in the U.S. and China, it hasn’t been reviewed by the U.S. Food and
Drug Administration. However, it is permitted for distribution and use
under the fast-tracked emergency guidelines of the agency.
https://www.marketscreener.com/BECTON-DICKINSON-AND-COM-11801/news/Becton-Dickinson-and-BioMedomics-to-Release-Rapid-Covid-19-Detection-Test-30285169/
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.